A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)

Trial Profile

A Pilot Clinical Trial of CPI-613 in Patients With Relapsed or Refractory Small Cell Lung Carcinoma (SCLC)

Discontinued
Phase of Trial: Phase I

Latest Information Update: 03 Aug 2017

At a glance

  • Drugs CPI 613 (Primary)
  • Indications Small cell lung cancer
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2016 This study has been closed early due to lack of efficacy, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Status changed from active, no longer recruiting to discontinued, as per an abstract presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
    • 07 Jun 2016 Results presented at the 52nd Annual Meeting of the American Society of Clinical Oncology
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top